Previous Close | 2.42 |
1-Year Change | -15.68% |
6-Months Change | -18.24% |
3-Months Change | 9.5% |
Moving Avg (50d) | 2.4322 |
Moving Avg (200d) | 2.5089 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 97.5M |
Beta (3-Years) | 1.48 |
Revenue Growth (ttm) | -16.77% |
Net Profit Margin (ttm) | -894.21% |
Return On Assets (ttm) | -8.69% |
EPS (ttm) | 0.49 |
PE Ratio (ttm) | 4.94 |
Dividend Yield | % |
Asset Description: | Oramed Pharmaceuticals Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
2.372 | 2.299 | 2.251 | 2.178 | 2.057 | 1.936 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |